CagriSema 10mg (Blend)

▎ He aha ka Semaglutid?

ʻO Semaglutid, ma ke ʻano he glucagon-like peptide-1 (GLP-1) receptor agonist lōʻihi, ua hoʻohana nui ʻia i ka lāʻau lapaʻau o ka maʻi diabetes type 2. Ma ka hoʻohālikelike ʻana i nā hana physiological o ka GLP-1 maoli, ua hoʻoulu kēia lāʻau i nā mīkini hoʻoponopono metabolic he nui ma hope o ka hoʻāla ʻana i ka mea hoʻokipa GLP-1, me ka hoʻonui ʻana i ka huna ʻana o ka insulin i hilinaʻi i ka glucose, ka hoʻoponopono pale ʻana i ka hoʻokuʻu ʻana o ka glucagon, ka lohi o ka hoʻokaʻawale ʻana o ka ʻōpū, a me ka hopena hoʻopau ʻana i ka ʻai waena, a laila e loaʻa ai ka hopena synergistic o ke koko glucose a me ka hoʻokele paona. ʻO kāna mau waiwai pharmacokinetic kūʻokoʻa e hāʻawi iā ia me ka hapalua o ke ola a hiki i 7 mau lā, e kākoʻo ana i kahi regimen injection subcutaneous i hoʻokahi pule a i ʻole ke ʻano hoʻokele waha i kēlā me kēia lā, kahi e hoʻomaikaʻi nui ai i ka ʻike lapaʻau o nā maʻi a hoʻomaikaʻi i ka mālama ʻana i ka lāʻau.

Hōʻike ka ʻikepili hoʻokolohua maʻi e hiki i ka semaglutide ke hoʻemi nui i ke kiʻekiʻe o ka hemoglobin glycated (HbA1c) a hiki i 1.8%, a he haʻahaʻa loa ka hopena o nā hanana hypoglycemic, e hāʻawi iā ia i kahi pono kūʻokoʻa i ka hoʻokele glucose koko. Eia kekahi, ua hōʻoia piha ʻia ka hopena pale cardiovascular o kēia lāʻau lapaʻau, hiki ke hōʻemi i ka hopena o nā hanana cardiovascular koʻikoʻi e 26%, e hāʻawi ana i nā pono therapeutic hou no nā poʻe maʻi maʻi me nā maʻi cardiovascular. Ma waho aʻe o ka mālama ʻana i ka maʻi diabetes, hiki ke hoʻohana ʻia ka semaglutide no ka hoʻokele lōʻihi o ka momona a ua hōʻike i ka waiwai therapeutic kūpono i ka noiʻi ʻana i nā maʻi e like me ka steatohepatitis non-alcoholic a me ka maʻi o Alzheimer.

ʻO kēia kaʻina hana lapaʻau multi-target e pili ana i ka hoʻoulu ʻana o ka receptor GLP-1 ʻaʻole wale e hoʻonui i nā ʻāpana metabolic ma o ka hoʻomaikaʻi ʻana i ka naʻau o ka insulin, kaohi ʻana i ka huna ʻana o ka glucagon nui, a me ka hoʻoponopono ʻana i ke kikowaena o ka ikehu waena, akā hāʻawi pū kekahi i kahi hoʻolālā lapaʻau no ka hoʻokele piha ʻana i nā maʻi metabolic maʻi ma o ka hopena pale cardiovascular a me nā pono kūpono o ka ʻōnaehana nerve waena. ʻO kona hiki ke hoʻohana i nā wahi maʻi he nui e hōʻoia hou i ke kūlana koʻikoʻi o ka GLP-1 receptor agonists ma ke ʻano he kumu lapaʻau i ka lāʻau lapaʻau metabolic hou.

▎ Hōʻuluʻulu manaʻo

ʻO ka hui pū ʻana o Cagrilintide a me Semaglutid (Cagrisema) e hōʻike ana i nā hopena synergistic koʻikoʻi i ka mālama ʻana i ka momona a me ke ʻano diabetes mellitus type 2. Hoʻokō ʻia kēia hui ʻana i ka hoʻoponopono multi-dimensional o ka makemake, ka metabolism glucose koko, a me ka hoʻokele paona ma o ka huli ʻana i ka amylin a me GLP-1 receptors. Hoʻoponopono ʻo Cagrilintide ma o ka hoʻokuʻu ʻana o ka ʻōpū a me ka hoʻoponopono satiety waena, ʻoiai ʻo Semaglutid e kāohi i ka huna ʻana o ka glucagon a hoʻonui i ka huna ʻana o ka insulin. ʻO ka hopena synergistic o nā mea ʻelua e hoʻonui nui i nā hopena o ke kaumaha o ke kaumaha a me ka hoʻokele glucose koko.

Hōʻike nā hōʻike hōʻike hoʻokolohua ʻo Cagrisema (ka hui pū ʻana o Cagrilintide 2.4mg a me Semaglutid 2.4mg) i ka awelika o ka pohō kaumaha o 9.07% (he pohō kaumaha loa o 9.11kg) i ka wā mālama o 20 a 32 wiki, ʻoi aku ka maikaʻi ma mua o ka mālama ʻana o ka hoʻohana ʻana iā Semaglutid 2 wale ^nō . Ma kahi 32-week, multicenter, double-blind, phase 2 clinical trial, ʻoi aku ka nui o ka pohō kaumaha o nā maʻi i mālama ʻia me CagriSema ma mua o nā maʻi i mālama ʻia me Semaglutid a i ʻole Cagrilintide wale nō. 

ʻO ka poho kaumaha ma ka hui CagriSema he -15.6%, aia ma ka hui Semaglutid -5.1%, a ma ka hui Cagrilintide he -8.1% ^[2] . Eia kekahi, hana maikaʻi ʻo Cagrisema i ka hōʻemi ʻana i ka hemoglobin glycated (HbA1c) a me ka hoʻomaikaʻi ʻana i nā hōʻailona pilikia o ka maʻi cardiovascular, ʻoiai ka haʻahaʻa loa o ka pilikia o ka hypoglycemia. Ma o ka mīkini multi-target, ʻaʻole i hoʻopaʻa wale kēia regimen lāʻau lapaʻau i nā ʻāpana metabolic akā e hōʻemi nui hoʻi i ka hopena o nā hanana cardiovascular, e hāʻawi ana i kahi koho lapaʻau piha loa no nā poʻe maʻi me ka momona a me ke ʻano diabetes mellitus type 2.

No ka mea kakau

ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.

▎Nā Kuhikuhi Pili

[1] Dutta D, Nagendra L, Harish BG, et al. ʻO ka maikaʻi a me ka palekana o Cagrilintide wale nō a me ka hui pū me Semaglutid (Cagrisema) ma ke ʻano he Anti-Obesity Medications: He Systematic Review and Meta-Analysis [J]. Nūpepa Inia o Endocrinology a me Metabolism, 2024,28:436-444.DOI:10.4103/ijem.ijem_45_24.

[2] Frias JP, Deenadayalan S, Erichsen L, et al. ʻO ka maikaʻi a me ka palekana o ka cagrilintide 2·4 mg i hoʻokahi pule i kēlā me kēia pule me ka semaglutide 2 · 4 mg i hoʻokahi pule i ka maʻi diabetes type 2: he multicentre, randomized, double-blind, active-controlled, phase 2 trial [J]. Lancet, 2023,402(10403):720-730.DOI:10.1016/S0140-6736(23)01163-7.

ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.  

ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a i ʻole maʻi. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.